ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
MWN-AI** Summary
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing innovative therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, is set to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place on February 11-12, 2026, in New York City. The company's participation includes a fireside chat scheduled at 9:30 AM ET on February 11, with a live webcast available on their website for 30 days following the event.
ProMIS is renowned for its proprietary EpiSelect™ target discovery engine, which identifies Disease Specific Epitopes (DSEs) on misfolded proteins that lead to neurodegenerative diseases, including AD, amyotrophic lateral sclerosis (ALS), and Parkinson’s Disease (PD). Their leading candidate, PMN310, is a humanized monoclonal antibody specifically designed to target toxic oligomers associated with AD, potentially minimizing the risk of amyloid-related imaging abnormalities (ARIA) by avoiding binding to plaques.
The ongoing PRECISE-AD clinical trial will evaluate PMN310 in patients with mild cognitive impairment and mild AD, focusing on safety, tolerability, and efficacy. This Phase 1b trial is notable for being the first to assess a monoclonal antibody directed solely against toxic A?O oligomers, with an emphasis on monitoring ARIA risk.
The innovative approach of ProMIS, utilizing the EpiSelect™ platform to generate selective therapeutic antibodies, represents a paradigm shift in treating neurodegenerative diseases. This participation in the Guggenheim Summit marks an important opportunity for ProMIS to showcase their promising advancements in neurology therapeutics and engage with potential investors about their research and clinical developments. For further details, visit their website or reach out to their investor relations team.
MWN-AI** Analysis
ProMIS Neurosciences, Inc. (Nasdaq: PMN) is poised to make significant strides in the biotech sector, particularly concerning Alzheimer’s Disease (AD). Their participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 offers a strategic opportunity to showcase their innovative approach to neurodegenerative diseases and attract investor interest.
ProMIS's lead candidate, PMN310, has the potential to redefine AD treatment through its unique mechanism of selectively targeting toxic oligomers while sparing the less harmful monomers and plaques. This specificity could reduce adverse effects like Amyloid-Related Imaging Abnormalities (ARIA), a concern with existing therapies. The recent Fast Track designation by the FDA underscores the urgency and promise surrounding PMN310, especially following encouraging Phase 1a trial results.
Investors should closely monitor the outcomes of the ongoing PRECISE-AD trial, which is critical in establishing PMN310’s safety and efficacy profile. The trial's design is robust, targeting biomarkers that are crucial to understanding the clinical implications of the treatment, which could position ProMIS favorably within a competitive landscape. Positive data could catalyze stock price gains and bolster confidence in further clinical advancements.
Given the rising prevalence of Alzheimer’s disease and the pressing need for effective treatments, ProMIS is well-placed to take advantage of both market demand and evolving healthcare paradigms. The strategic use of their EpiSelect™ technology to differentiate their therapies from traditional approaches presents a unique selling proposition that could attract substantial interest amidst investors looking for innovation in the biotech space.
In conclusion, ProMIS represents a compelling opportunity for those willing to engage with a high-risk, high-reward segment of biotech, especially as the company advances through critical clinical milestones and engages with prospective investors at the summit.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY.
The fireside chat will be held at 9:30am Eastern Time on Wednesday, February 11th and a live webcast of the presentation may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com. The webcast will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)
PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing, or eliminating amyloid-related imaging abnormalities (ARIA) liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.
Based on the encouraging results from the Phase 1a trial (NCT06105528) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against A?O on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide sufficient power to provide meaningful insight into effects of PMN310 on biomarkers and clinical outcomes.
EpiSelectTM Drug Discovery Engine
Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelectTM) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-speci?c antibodies or vaccine formulations. Application of the ProMIS platform produced PMN310, a clinical stage, humanized monoclonal antibody candidate that has been shown to be highly selective for toxic amyloid-beta oligomers (A?O) without signi?cant reactivity with amyloid-beta monomers or ?brils, thereby avoiding target distraction by these more abundant species, and potentially reducing the risk of brain edema and microhemorrhages associated with the targeting of vascular/parenchymal amyloid. Similarly, speci?c epitopes for alpha-synuclein toxic oligomers/soluble ?brils that drive synucleinopathies, and for pathogenic TDP-43 in ALS and FTD have been identified and lead candidate antibodies generated. The precise conformation of these epitopes has been translated into vaccines inducing an antibody response selective for pathogenic molecular species in preclinical mouse vaccination studies.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com
For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com
FAQ**
How does ProMIS Neurosciences' development of PMN3compare to the advancements made by Amorfix Life Sciences Ltd ARFXF in addressing neurodegenerative diseases, particularly in terms of safety and efficacy profiles?
Given the focus on neurodegenerative disorders, what differentiates ProMIS Neurosciences' EpiSelect™ platform from technologies employed by Amorfix Life Sciences Ltd ARFXF in targeting misfolded proteins?
In the context of the PRECISE-AD trial, what potential implications could the results hold for investors, especially when comparing them to similar trials or products developed by Amorfix Life Sciences Ltd ARFXF?
How might ProMIS's approach with PMN310 and its selective targeting play into the larger landscape of neurodegenerative therapies, particularly those being explored by competitors like Amorfix Life Sciences Ltd ARFXF?
**MWN-AI FAQ is based on asking OpenAI questions about ProMIS Neurosciences Inc. (NASDAQ: PMN).
NASDAQ: PMN
PMN Trading
-0.72% G/L:
$24.20 Last:
17,471 Volume:
$22.79 Open:
